BioVoice News eMag October 2024 | Page 24

S P E C I A L I N T E R V I E W

Data Specialists ) and patient-based clinical trials in India . Secondly , the Healthy Volunteer Services portfolio will include operations in Gujarat ( India ) including clinical bioanalysis for small molecules . Thirdly , the preclinical and non-clinical testing services of Veeda ( based in Karnataka ) will cater to clients in pharma and biotech industry along with agrochem and industrial chemicals . This includes our discovery research services in the area of chemistry and biology . Fourth is Biopharma Services based in Bengaluru that will include analytical characterization and functional characterization of biologics along with cell line and process development and clinical bioanalysis of large molecules .
We continue to become strong and versatile in offering impeccable services to our clients .
What are the most significant current trends you are observing in the clinical research industry in India and globally ?
AI and ML are playing a significant role in enhancing various aspects of clinical trials , including patient recruitment , data analysis , and trial monitoring . These technologies are expected to streamline processes and improve the accuracy of trial outcomes . For example , in a recent study , Deep Learning Networks ( DLN ) were used to repurpose existing drugs with proven activity against SARS-CoV , HIV , and Influenza viruses , and researchers concluded that thirteen of the screened drugs should be investigated further for potential
With 33 + years of global experience with leading drug discovery and development companies , Dr Mahesh Bhalgat has served in senior leadership roles in many top companies . Prior to this , he was the COO of Syngene International and also at the key positions in Sanofi , and Biological E Limited . Earlier Mahesh spent 20 years in the US completing his PhD and working with multi-national pharma giants such as Amgen and Monsanto . development for fighting other viral diseases . AI is being first used in clinical trial design to collate , harmonize , and reconcile disparate datasets .
The shift towards decentralized and hybrid clinical trials continues to grow . The number of DCTs has surged , especially during the COVID-19 pandemic . For instance , the number of DCTs reported on clinicaltrials . gov increased by 77 % between 2019 and 2020 , and by another 34 % between 2020 and 2021 . Approximately 1,300 trials with decentralized or virtual components were initiated in 2022 , marking a 28 % increase from 2021 . These models , which incorporate remote monitoring and digital health tools , are making trials more accessible and efficient .
There is a growing trend towards outsourcing clinical trials to India due
24
BioVoiceNews | October 2024